Health Tech Daily Brief - September 28, 2026

Deep Origin deploys AI-powered ADMET models across drug discovery programmes

Daewoong Pharmaceutical Expands AI into Drug Formulation Design with $4 Million Government Project

Healthcare executives are still investing in tech as AI’s bill comes due, survey finds

Insurer telehealth gambit proves popular

Cuvo Health Publishes 2026 State-by-State Virtual Clinic Compliance Report: 33 of 51 Jurisdictions Restrict the Corporate Practice of Medicine

Anambra records 2,500 free HIV tests, expands access to Telehealth

Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care

Continuous glucose monitoring may lower mortality risk in diabetic patients on insulin

Investors go loopy for Oura’s smart rings before $15bn float

California Critical Access Hospital Announces Cybersecurity Incident

Blockchain in Healthcare Market Size Set to Reach USD 62.19

Patient Portals Market to Reach USD 15.46 Billion by 2033 at 17.5%

Lupin receives tentative FDA approval for novel apixaban oral suspension

Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder

Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year. The post Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder appeared first on MedCity News.

LegitScript tops 10,000 certified websites as health ad gatekeeper

‘ChatGPT for Doctors’ OpenEvidence Raises $250M, Quietly Pivots Into Drug Development

The Weekly Notable Startup Funding Report: 9/28/26

Egyptian Healthcare Startup Anees Health Raises Seed Funding To Expand Care

Texas Built An AI Chatbot For Its Regulations